Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RORER MAALOX OTC COMBINATION WITH H[2] ANTAGONIST

Executive Summary

RORER MAALOX OTC COMBINATION WITH H[2] ANTAGONIST is under consideration by the company, Exec VP Ralph Thurman told analysts at a Nov. 21 research conference sponsored by Mabon Nugent. Thurman noted that the recent J&J/Merck purchase of ICI's OTC business and the resulting possibility of a Pepcid (famotidine)/Mylanta combination has "quadrupled the interest by people who have H[2] [compounds] to align themselves with Maalox." Rorer is "in the midst . . . of discussions" about a possible combination product, he reported. * Thurmond did not specify which H[2] antagonist the company is contemplating. However, he identified Glaxo's Zantac (ranitidine) as the product thought to be the best H[2] "by most people's measures." OTC rights to Zantac are held by Sandoz. Thurmond also indicated that SmithKline's Tagamet (cimetidine) would be an unlikely partner for Maalox. Commenting on industry speculation of a combination Tagamet/Tums product now that SmithKline and Beecham are merged, Thurmond said such a product would have a "dual problem": Tums is an established tablet product, but not an established liquid; and "Tagamet is not by a long stretch of the imagination the best H[2] today." From what Rorer knows, he continued, "formulating the product in an OTC version is a great problem, and Tagamet also suffers another problem -- it tastes lousy. So, they've got a big challenge in front of that." Rorer is balancing the idea of blending Maalox with an existing H[2] antagonist against the possibility of developing its own H[2]/Maalox combo, Thurmond said. Noting that the Maalox brand "has a 99% consumer awareness" he said: "My own question has to be, are we giving away more by lending the Maalox name to an H[2] product than we are getting in return by receiving the H[2], as opposed to being a year or two late to the market with our own H[2] and retaining 100% ownership of the brand." Asked whether the generic investigation of Bolar may jeopardize Rorer's joint venture with the firm for development of diltiazem products, Thurmond said he did not believe the project would be affected, but noted that Rorer could "go it alone" if necessary. "The impact of whatever may happen [to Bolar] in the future is minimal at best on our diltiazem strategy," Thurmond said. "We entered into the Bolar joint venture primarily to gain access to the toxicology package that they had done on their product . . . and we have the rights to the [that] package. We are preparing the NDA filing essentially with Rorer resources anyway, so we are fully prepared to go it alone if they can't be a good partner."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel